ADARx Pharma files for Nasdaq IPO

ADARx Pharmaceuticals has submitted documents for a proposed initial public offering on the Nasdaq Global Market, seeking to list its shares under the ticker symbol ADRX. The filing marks a step toward becoming a publicly traded company but leaves several key terms of the transaction unspecified at this stage.

In the initial notice, ADARx did not disclose the planned timing of the IPO or the size of the offering. The documents also do not include information such as the proposed number of shares to be sold, the expected price range, or other detailed financial terms that are typically set out closer to the marketing of the deal.

The proposed offering is supported by a syndicate of investment banks. J.P. Morgan and Morgan Stanley (MS) are listed among the lead underwriters, alongside TD Cowen, UBS Investment Bank and LifeSci Capital. Their role will include advising on the offering structure, helping determine valuation parameters, and placing shares with institutional and other investors once terms are finalized.

The company has indicated the Nasdaq Global Market as the intended listing venue, signaling a plan to access a broad base of equity investors. However, without a disclosed timetable or offering size, the overall scale of the planned capital raise remains undefined in the current materials.

ADARx characterizes itself as a late-clinical-stage biotechnology company focused on developing therapeutics based on small interfering RNA, or siRNA. This approach is aimed at modulating specific molecular targets through RNA interference, though the filing materials available center on corporate and pipeline status rather than detailed scientific data.

The company reports a pipeline that includes three clinical-stage programs and two advanced preclinical programs. These programs represent the core assets that will underpin investor assessment of the business as it moves toward the public markets. The filing positions these programs as the main drivers of the company’s development activities and prospective growth.

Further information on the individual programs, as well as more granular financial and strategic details about the planned IPO, is expected to be provided in subsequent regulatory documents. Until those are filed, the available information mainly outlines the company’s stage of development, focus on siRNA therapeutics, and the basic framework of the proposed listing.